News

Gastrointestinal Symptoms Common in CF; Women Most Affected

Adults and children with cystic fibrosis (CF) frequently have moderate to severe gastrointestinal (GI) symptoms such as fullness and bloating, and women are primarily affected, new research suggests. GI-targeted medications were largely not effective and both age groups reported being highly dissatisfied with them. The study, “Multicentre prospective…

#NACFC2022 – Trikafta Helps to Resolve Inflammation in CF: Study

Treatment with the triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) reduces inflammation and promotes lung tissue repair in cystic fibrosis (CF), new research indicates. Nicola Robinson, MD, from The University of Edinburgh, presented the findings at the 2022 North American Cystic Fibrosis Conference, in the talk “Elexacaftor/Tezacaftor/Ivacaftor treatment promotes inflammation…

#NACFC2022 – Trikafta Patients Report Better Quality of Life

People with cystic fibrosis (CF) tend to report improvements in health-related quality of life associated with treatment with Trikafta. Reports of worse mental health were common, however, and were identified as an area of need. That’s according to data shared by Aricca Van Citters, from The Dartmouth Institute for Health Policy & Clinical Practice,…

#NACFC2022 – LAU-7b May Prevent Lung Function Decline in CF

Treatment with LAU-7b, an oral form of fenretinide being developed by Laurent Pharmaceuticals, may help prevent lung function decline in adults with cystic fibrosis (CF), particularly those with mild disease, according to results from a Phase 2 clinical trial. Larry Lands, MD, PhD, the company’s chief medical…